Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.
DECREASE: Phase II DarolutamidE + Consolidation RadiothErapy in Advanced proStatE cancer detected by PSMA
Sponsor / Cooperative group:
Trans Tasman Radiation Oncology Group (TROG)